By: ABRS- Clinical Insights Team
Abstract
The economic evaluation of Functional Service Provider (FSP) partnerships in clinical research requires consideration of factors beyond contracted service rates and personnel costs. As sponsors increasingly rely on external functional expertise to support clinical development, understanding the financial implications of these arrangements is essential for informed outsourcing decisions. This article examines the economic dimensions of FSP partnerships through a narrative analysis of published research on clinical trial costs, outsourcing practices, resource allocation, and operational management. Particular attention is given to retained sponsor responsibilities, professional onboarding, resource utilization, contractual flexibility, and the financial consequences of changing study requirements. The analysis highlights how coordination activities and internal management resources can influence the total cost of functional outsourcing. It also identifies limitations in the available evidence, particularly the lack of standardized economic comparisons between FSP and full-service outsourcing arrangements. Rather than assuming that functional outsourcing consistently reduces expenditure, the article emphasizes the importance of evaluating total resource requirements, contractual structures, and operational demands. A comprehensive economic assessment can provide sponsors with a more informed basis for determining how FSP partnerships align with their clinical development needs and financial planning objectives.
Introduction
Clinical trial outsourcing is frequently associated with the need to manage development costs, access specialized expertise, and respond to changing operational requirements. For sponsors, however, the financial implications of outsourcing extend beyond the price of external services. The resources required to coordinate activities, integrate professionals, maintain quality, and respond to unexpected changes can influence the overall economic value of a clinical research partnership.
The Functional Service Provider (FSP) model offers an arrangement in which sponsors obtain support for selected clinical research functions while retaining defined responsibilities within their organizations. Depending on the agreement, these functions may include clinical monitoring, study start-up, regulatory affairs, pharmacovigilance, data management, or other specialized activities.
Although functional outsourcing can provide opportunities to adjust resource capacity according to program requirements, its financial value cannot be determined solely by comparing the cost of external professionals with the salaries of internal employees.
Research on the economics of clinical trials demonstrates why a broader assessment is necessary. Sertkaya et al. (2016), in a study published in Clinical Trials, examined expenditure patterns across different therapeutic areas and development phases. The authors identified clinical procedures, administrative personnel, and site monitoring among the principal direct cost drivers. Their findings illustrate that clinical trial expenditures arise from multiple interacting operational requirements rather than a single category of spending.
Similarly, Getz et al. (2014), in Clinical Therapeutics, examined outsourcing relationships across pharmaceutical and biotechnology companies and found that sponsors frequently combined different sourcing arrangements within their clinical development programs. The researchers identified coordination challenges associated with these arrangements, suggesting that the financial and operational value of outsourcing depends partly on how external services are organized.
These considerations are particularly relevant to FSP partnerships because the sponsor and provider may share responsibility for different aspects of functional execution and management.
Understanding the economics of an FSP arrangement therefore requires examining the total resources involved, the relationship between capacity and workload, and the financial implications of coordinating clinical research activities across organizations.
Beyond Contract Rates: Understanding the Full Cost of Functional Outsourcing
One of the most important considerations when evaluating an FSP partnership is the distinction between the contracted price of a service and the total cost of obtaining and managing that service.
An FSP agreement may specify fees associated with professional resources, defined deliverables, or other contractual arrangements. These fees provide a basis for financial planning, but they do not necessarily account for every resource the sponsor must allocate to support the partnership.
For example, external Clinical Research Associates (CRAs) may require onboarding, access to sponsor systems, study-specific training, and coordination with internal Clinical Trial Managers. Sponsor personnel may also spend time reviewing deliverables, managing resource assignments, communicating operational expectations, and addressing issues that arise during execution.
These activities can generate internal costs even when the clinical monitoring work itself is performed by an external provider.
Amatya and Edgerton (2021), in the Journal of the Society for Clinical Data Management, examined vendor selection and management in clinical research. Their review emphasizes the importance of defining service expectations, responsibilities, communication processes, and oversight arrangements. Although the publication does not calculate the financial return of FSP models, it identifies management activities that sponsors need to consider when organizing outsourced functions.
From an economic perspective, these retained activities matter because external service fees represent only part of the resources required to operate the relationship.
Research on clinical trial budgeting offers additional context.
Nevens et al. (2019), in Trials, described the development of an activity-based budgeting tool for non-commercial multicenter clinical trials. Their approach categorized trial-related activities and identified cost drivers across sponsor and investigative-site operations, allowing resources to be estimated according to the work required.
Although this methodology was developed for publicly funded research rather than specifically for commercial FSP arrangements, its underlying principle is relevant: financial planning becomes more transparent when costs are associated with identifiable activities instead of broad budget categories alone.
For an FSP partnership, an activity-based perspective can help sponsors distinguish between resources provided externally and responsibilities maintained internally.
Consider a hypothetical sponsor evaluating external monitoring support. The contracted service may cover the assignment of qualified CRAs and their monitoring activities. However, the sponsor may still need internal personnel to oversee monitoring strategy, evaluate significant findings, coordinate escalations, and manage the interface between external monitoring professionals and other study functions.
The economic assessment should therefore consider both the contracted services and the sponsor resources necessary to support them.
A related concern is the possibility of duplicated responsibilities.
When contractual boundaries are insufficiently defined, different organizations may perform overlapping coordination, reporting, or administrative activities. These arrangements can increase resource consumption without necessarily providing additional operational value.
Getz et al. (2014) observed that organizations frequently combined several outsourcing models within individual clinical studies. Their analysis identified internal friction and coordination challenges that could limit the anticipated benefits of strategic outsourcing relationships.
This evidence does not establish a specific monetary penalty for overlapping responsibilities in FSP partnerships. Nevertheless, it supports the importance of examining how internal and external activities are distributed.
The economic value of functional outsourcing should therefore be evaluated through a complete understanding of contracted expenditure, retained sponsor responsibilities, and the operational resources required to coordinate both.
Resource Utilization, Operational Changes, and Financial Predictability
Another important dimension of FSP economics is the relationship between resource availability and actual clinical development workload.
Clinical trials rarely require identical levels of functional support throughout their lifecycle. Study start-up, active enrollment, ongoing monitoring, protocol amendments, and closeout activities create different operational demands.
An FSP arrangement can provide a contractual framework for adjusting functional resources as these demands change. However, the economic implications depend on how the agreement addresses resource allocation, minimum commitments, utilization, reassignment, and changes in scope.
An organization that maintains more professional capacity than its studies require may incur costs associated with underutilized resources. Conversely, insufficient capacity may create operational pressures, additional recruitment needs, or delays in performing assigned activities.
The objective of functional resource planning is therefore not simply to minimize personnel numbers. It is to establish an appropriate relationship between available capacity and the work required to conduct clinical research activities.
Jones and Minor (2010), writing in Perspectives in Clinical Research, discussed the development of strategic outsourcing arrangements, including functional service partnerships. The authors described opportunities to align external resources with sponsor processes and highlighted the importance of early planning, governance, and coordinated relationships.
Their article includes examples of reported process and cost improvements associated with functional outsourcing. However, these examples were presented as industry experiences rather than results from a controlled comparative economic evaluation. They should not be interpreted as evidence that FSP partnerships consistently achieve a predetermined level of savings.
This distinction is important when sponsors assess proposals that emphasize flexibility or resource efficiency.
Financial predictability also depends on how contractual arrangements respond to unexpected operational changes.
Clinical development programs may require additional resources because of revised study timelines, expanded geographic coverage, changes in protocol procedures, or modifications to monitoring requirements.
The financial significance of such changes has been examined in clinical research literature.
Getz et al. (2016), in Therapeutic Innovation & Regulatory Science, analyzed the prevalence and consequences of substantial protocol amendments. The study examined 836 protocols to assess amendment prevalence and used smaller subsets to evaluate amendment-related impacts and costs. The researchers reported median direct implementation costs of approximately US$141,000 for a substantial Phase II amendment and US$535,000 for a substantial Phase III amendment.
These historical figures reflect the protocols and organizations included in the study and are not estimates of FSP-specific expenses.
Nevertheless, the findings demonstrate that changes in trial requirements can introduce substantial unplanned costs. Such changes may also affect the type, timing, and volume of external functional support required.
For an FSP partnership, a protocol amendment might lead to additional CRA training, revised monitoring activities, updated documentation processes, or greater demands on other clinical research functions.
Whether these activities generate additional contractual charges depends on the scope of the agreement and the arrangements established between the sponsor and provider.
These considerations suggest that financial planning should evaluate not only the initial allocation of resources but also the mechanisms available for modifying assignments when study requirements change.
More recent research highlights the broader challenge of accurately estimating clinical research expenditures.
Griessbach et al. (2025), in a meta-research study published in Trials, examined budgeting approaches used by seven Swiss clinical trial units and the Swiss National Science Foundation. The researchers identified substantial variation in budgeting methods and found that the reviewed approaches had not undergone user testing or provided cost ranges that investigators could use for estimation.
Although the study focused on academic clinical research rather than commercial outsourcing, it illustrates the limitations of financial planning when cost definitions and estimation methods are inconsistent.
For sponsors using an FSP model, these findings support the value of clearly defined budgeting assumptions, transparent cost categories, and systematic review of resource requirements.
Financial predictability should therefore not be understood as the absence of change. Rather, it involves establishing sufficiently clear contractual and operational processes to identify changes, assess their financial implications, and make informed resource-allocation decisions.
Evaluating the Economic Value of an FSP Partnership
Determining whether an FSP partnership provides economic value requires a broader assessment than comparing service rates or calculating the cost of individual professionals.
A meaningful evaluation should consider the total expenditure associated with the arrangement, the resources required to manage it, the suitability of the assigned professionals, and the relationship between service costs and completed activities.
This perspective is particularly important when sponsors compare functional outsourcing with maintaining internal capacity or engaging a full-service CRO.
An FSP arrangement may allow an organization to obtain specialized resources without expanding every internal department. However, the sponsor may also need to retain management capabilities that would be organized differently under another outsourcing structure.
As a result, the financial comparison depends on which responsibilities are included in each option.
For example, comparing a contracted CRA rate with an employee’s base salary would not provide a complete assessment. Internal employment involves additional costs, including benefits, training, supervision, infrastructure, and potentially periods of lower utilization. External arrangements may involve service fees, onboarding, coordination, vendor management, contractual commitments, and transition expenses.
The relevant comparison is therefore between the total costs of delivering equivalent functions under clearly defined operating arrangements.
Research on the efficiency of research service organizations provides another perspective.
Díaz and Sanchez-Robles (2023), in Economic Research-Ekonomska Istraživanja, applied data envelopment analysis to examine the relative efficiency of international CROs between 2012 and 2020. Their findings identified differences in organizational efficiency and suggested that firm size and specialization may influence how research service providers use their resources.
The study evaluated efficiency within the CRO industry. It did not directly compare the costs incurred by sponsors under FSP and full-service contracts, nor did it establish that functional outsourcing is economically superior.
However, it reinforces the importance of assessing the operational capabilities of service providers rather than assuming that organizations offering similar services have equivalent resource structures.
Beyond provider characteristics, the economics of an FSP relationship are also influenced by the sponsor’s ability to coordinate outsourced activities.
Wilkinson et al. (2020), in Therapeutic Innovation & Regulatory Science, examined outsourcing oversight practices using responses from 88 individuals involved in clinical development. More than half of respondents reported using at least three outsourcing models simultaneously. The researchers identified opportunities to strengthen oversight through management involvement, communication, collaboration, and technology.
While the study did not quantify the financial returns of these improvements, its findings demonstrate that outsourcing relationships require management structures that extend beyond the initial contracting decision.
For sponsors, the implication is that oversight and coordination should be recognized as necessary components of the operating model rather than treated as activities that occur without resource consequences.
A practical economic assessment should also consider the expected duration of the relationship.
A short-term functional requirement may involve substantial onboarding and coordination relative to the amount of work performed. A longer-term arrangement involving multiple studies may create opportunities to reuse established processes and retain organizational knowledge, although these benefits depend on continuity, contractual terms, and actual resource utilization.
The financial implications of either arrangement cannot be determined without examining the specific program.
From this perspective, sponsors can assess FSP economics across several connected dimensions: contracted service expenditure, retained internal management costs, resource utilization, onboarding and transition requirements, operational changes, and the resources needed to maintain appropriate quality and oversight.
Such an assessment would provide a more complete basis for comparing outsourcing alternatives, although the availability and reliability of cost data may limit the precision of the resulting estimates.
At Advanced BioResearch Solutions (ABRS), the FullSpectrum FSP model provides a framework for aligning specialized clinical research support with sponsor and CRO operational requirements.
Within this approach, economic planning should begin with understanding the functions requiring support, the professional capabilities necessary to perform them, the anticipated duration of assignments, and the responsibilities retained by the sponsor.
For programs requiring regional clinical monitoring, study start-up support, or other specialized services, the relevant financial consideration is not simply the number of professionals assigned. It is whether the allocation of functional resources corresponds to the study’s actual operational demands.
A clear understanding of these requirements can help inform contracting discussions, resource planning, and the management of changes throughout the clinical trial lifecycle.
Importantly, the available evidence does not justify claiming that the FSP model consistently reduces costs compared with alternative outsourcing structures. Direct, standardized comparisons of total sponsor costs across different functional outsourcing arrangements remain limited.
The more defensible economic argument is that a well-structured FSP partnership offers sponsors a way to organize external capabilities around defined functional requirements, with potential financial value depending on utilization, coordination, contractual design, and the circumstances of the clinical program.
Functional Integration Without Blurring Responsibilities in the FSP Model
Clinical trial closeout demonstrates why functional integration requires more than assigning multiple professionals to the same study.
Clinical Monitoring, Clinical Oversight Management, and independent GCP auditing contribute different types of information and judgment. Their activities may intersect, but their purposes and decision-making boundaries must remain distinguishable.
In a sponsor-integrated FSP structure, monitoring professionals may conduct the assigned site-level reviews and document outstanding findings. COM professionals may support oversight of monitoring activities, evaluation of risks across sites, coordination of escalations, and visibility into unresolved operational responsibilities.
Independent auditors, when engaged, evaluate the relevant processes without participating in the execution or oversight of the activities they are assigned to audit.
The sponsor remains responsible for defining these activities, maintaining appropriate oversight, and determining how significant findings should be addressed.
ICH E6(R3), Section 3.6, recognizes that sponsors may transfer trial-related activities to service providers through documented agreements. Nevertheless, ultimate responsibility for sponsor trial-related activities, including participant protection and the reliability of trial results, remains with the sponsor (ICH, 2025).
This principle is especially relevant when services are delivered through embedded functional professionals who operate within sponsor systems and procedures.
Consider a hypothetical study approaching final site closeout. A CRA identifies a discrepancy involving investigational product accountability. The finding is documented and communicated in accordance with the monitoring plan.
The COM function, within its assigned scope, may evaluate whether the discrepancy is isolated, whether comparable issues have occurred elsewhere, and whether escalation to the sponsor’s quality or clinical personnel is warranted.
The sponsor’s designated personnel determine the appropriate response, taking into account the available evidence and applicable procedures.
If the sponsor’s independent audit program identifies a need to evaluate the investigational product accountability process, qualified auditors may examine the relevant records, procedural implementation, and management of identified discrepancies.
These activities are connected, but they are not interchangeable.
The CRA contributes direct information from site monitoring. COM supports sponsor visibility into the issue and its wider operational implications. The independent auditor, if an audit is conducted, assesses the applicable process without participating in its execution or remediation.
The FDA (2023) emphasizes that monitoring should focus on risks that matter to trial conduct and data reliability. In an integrated operational model, this principle can inform the information that monitoring professionals communicate and the issues that COM may need to follow up within its defined responsibilities.
Similarly, the EMA (n.d.) highlights the importance of clearly documented responsibilities when sponsors rely on contracted service providers. This consideration is particularly relevant when trial activities involve several organizations and records must remain accessible after operational services end.
Within ABRS’s FullSpectrum FSP model, Clinical Monitoring and Clinical Oversight Management provide a relevant context for the contribution of specialized professionals within sponsor-directed clinical operations. Independent GCP auditing can complement those functions when appropriately assigned, provided the required independence is maintained.
The value of this structure should not be assessed solely through the number of professionals assigned or the speed with which closeout milestones are completed.
More meaningful considerations include whether monitoring findings are accurately documented, whether significant risks are appropriately escalated, whether assigned follow-up is completed and supported by evidence, and whether independent quality assurance activities maintain their objectivity.
These considerations demonstrate that functional integration and clear responsibility boundaries are complementary requirements rather than competing objectives.
During study closeout, appropriately defined monitoring, COM, and auditing responsibilities can help sponsors understand the remaining state of trial execution while preserving their own accountability for final decisions.
Conclusion
The economics of Functional Service Provider partnerships cannot be understood through contracted service rates alone. Clinical research outsourcing creates a combination of external expenditures and internal operational responsibilities, both of which should be considered when evaluating financial value.
Research on clinical trial costs demonstrates the importance of understanding personnel requirements, monitoring activities, administrative work, and the consequences of changes during study execution. Studies examining outsourcing relationships further indicate that coordination, governance, and the distribution of responsibilities influence how external services are managed.
For sponsors, these findings support a comprehensive approach to financial planning that accounts for resource utilization, retained management functions, onboarding requirements, contractual flexibility, and the potential implications of changing study demands.
An FSP arrangement may offer opportunities to align specialized resources with a clinical development portfolio while maintaining established sponsor-led processes. However, these potential advantages should not be interpreted as automatic cost reductions or guarantees of superior economic performance.
The value of the model depends on whether the resources provided correspond to the work required, whether responsibilities are sufficiently defined, and whether the arrangement supports efficient coordination without compromising necessary quality and oversight activities.
Through its FullSpectrum FSP approach, ABRS seeks to connect specialized clinical research capabilities with the operational needs of sponsors and CROs. From an economic perspective, the relevance of this approach lies in supporting informed resource planning and aligning functional services with the requirements of individual clinical programs.
Ultimately, evaluating an FSP partnership requires moving beyond the question of how much an external professional or service costs. The more meaningful consideration is how effectively the combined resources of the sponsor and provider support clinical trial execution over the duration of the relationship.
Understanding these costs provides a stronger foundation for outsourcing decisions grounded in operational requirements, financial transparency, and appropriate allocation of clinical research resources.
References
Amatya, S., & Edgerton, D. (2021). Vendor selection & management. Journal of the Society for Clinical Data Management, 1(4). https://doi.org/10.47912/jscdm.118
Díaz, R. F., & Sanchez-Robles, B. (2023). Outsourcing of research and development and efficiency: A DEA non-parametric analysis of the contract research organisations industry. Economic Research-Ekonomska Istraživanja, 36(3), Article 2153374. https://doi.org/10.1080/1331677X.2022.2153374
Getz, K. A., Lamberti, M. J., & Kaitin, K. I. (2014). Taking the pulse of strategic outsourcing relationships. Clinical Therapeutics, 36(10), 1349–1355. https://doi.org/10.1016/j.clinthera.2014.09.008
Getz, K. A., Stergiopoulos, S., Short, M., Surgeon, L., Krauss, R., Pretorius, S., Desmond, J., & Dunn, D. (2016). The impact of protocol amendments on clinical trial performance and cost. Therapeutic Innovation & Regulatory Science, 50(4), 436–441. https://doi.org/10.1177/2168479016632271
Griessbach, A., Chiaborelli, M., Ehrlich, K., Grossmann, R., De Medina Redondo, M., Fayet, A., Maier, R., Trelle, S., Gayet-Ageron, A., Ceschi, A., Speich, B., & Briel, M. (2025). Clinical trial budgeting approaches in Switzerland—A meta-research study. Trials, 26, Article 158. https://doi.org/10.1186/s13063-025-08855-1
Jones, J., & Minor, M. (2010). New, strategic outsourcing models to meet changing clinical development needs. Perspectives in Clinical Research, 1(2), 76–79. https://pmc.ncbi.nlm.nih.gov/articles/PMC3148616/
Nevens, H., Harrison, J., Vrijens, F., Verleye, L., Stocquart, N., Marynen, E., & Hulstaert, F. (2019). Budgeting of non-commercial clinical trials: Development of a budget tool by a public funding agency. Trials, 20, Article 714. https://doi.org/10.1186/s13063-019-3900-8
Sertkaya, A., Wong, H.-H., Jessup, A., & Beleche, T. (2016). Key cost drivers of pharmaceutical clinical trials in the United States. Clinical Trials, 13(2), 117–126. https://doi.org/10.1177/1740774515625964
Wilkinson, M., Harper, B., Peacock, J., Morrison, R., & Getz, K. (2020). Assessing outsourcing oversight practices and performance. Therapeutic Innovation & Regulatory Science, 54(1), 158–166. https://doi.org/10.1007/s43441-019-00040-2
